1. Home
  2. OBIO

as of 02-17-2026 4:00pm EST

$3.84
$0.00
0.00%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Founded: 2017 Country:
N/A
Employees: N/A City: NEW HOPE
Market Cap: 237.2M IPO Year: N/A
Target Price: $14.25 AVG Volume (30 days): 187.5K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $2.20 - $5.98 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 36.66% Revenue Growth (next year): 2.30%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered OBIO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

hold
Model Accuracy: 73.81%
73.81%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Orchestra BioMed Holdings Inc. News

OBIO Breaking Stock News: Dive into OBIO Ticker-Specific Updates for Smart Investing

All OBIO News

Share on Social Networks: